Mortality in patients with dopamine agonist-treated hyperprolactinemia: a large matched-cohort study
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.972 95% CI 0.829–1.139Authors' conclusion
All-cause mortality in patients with DA-treated hyperprolactinemia is not increased compared to matched controls, however is higher in men vs. women. Mortality is primarily influenced by age, sex, BMI, and comorbidities. Achieving PRL normalization within a year decreases mortality compared with controls.
Study context
- Population
- Patients with dopamine agonist (DA)-treated hyperprolactinemia, Clalit Health Services database, 2000–2023; mean age 38.7 ± 14.8 years, 59.6% womenmatched cohort
- Participants
- 2,492 vs 12,456
- Exposure
- DA-treated hyperprolactinemia vs matched controls
- Patientsn = 2,492
- Controlsn = 12,456reference
- Outcome
- All-cause mortality
- Follow-up
- > 17 years
Methodological detailsnationwide, matched 1:5 by age, sex, socioeconomic status and BMI
- Nationwide
- Matched 1:5 by age, sex, socioeconomic status and BMI
Main finding
As reported in the abstract
Hazard ratio
0.972
95% CI 0.829–1.139
Events by group
Patientsvs Controls
HR 0.972 (95% CI 0.829–1.139)
Observational data: associations, not effects.
Secondary outcomes
Mortality by baseline PRL · lower mortality
HR 0.725
| Outcome | HR |
|---|---|
| Mortality by PRL normalization within 1 yearPRL normalization within 1 year vs Controls · lower mortality | 0.730 |
Mortality by prolactin (PRL) normalization within 1 year
- Patients without normalization had similar risk to controls
Mortality by sex
- Mortality higher in men than women with hyperprolactinemia but not vs controls
Causes of death
- Mainly infectious, cardiovascular and malignancies in both groups
Independent predictors of all-cause mortality
- Older age, higher BMI, male sex, HF, malignancy, hypertension, diabetes, ischemic heart disease
Original publication
Mortality in patients with dopamine agonist-treated hyperprolactinemia: a large matched-cohort study. Pituitary. Published 22 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →